All In Biotech

Drug Trial Radar · NCT03560986

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 267 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

267

Actual

Start

May 31, 2018

Primary completion

Aug 1, 2019

Study completion Aug 1, 2019

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
First posted
Jun 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial was to investigate the efficacy and safety of intravenous neridronic acid in subjects with Complex Regional Pain Syndrome (CRPS). The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A consisting of 4 infusions (neridronic acid 100 mg or placebo) over 10 days, and a Follow-up Period 1 until Week 26. At Week 26, participants meeting the pre-specified criteria entered the open-label Treatment Period B with 4 additional infusions (neridronic acid) over 10 days and follow-up visits until Week 52. Participants not meeting the pre-specified criteria to continue into Treatment Period B continued in Follow-up Period 2 until Week 52.

Conditions

  • Complex Regional Pain Syndrome (CRPS)

Interventions

  • Neridronic acid 100 mgDrug

    100 mg neridronic acid supplied in glass vials in 8 mL of excipients.

  • PlaceboDrug

    Glass vials with matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)Time frame: From the Baseline Phase (Day -7 to Day -1) to Week 12

Locations

71 sites in 7 countries. Site status is shown where the registry gives one.

  • US446 - Clinical Trial Connection

    Cottonwood, Arizona

  • US453 - Physicians Research Group II, LLC

    Tempe, Arizona

  • US428 - Quality of Life Medical and Research Center LLC

    Tucson, Arizona

  • US422 - Woodland International Research Group

    Little Rock, Arkansas

  • US454 - Alliance Research Institute

    Canoga Park, California

  • US415 - Clearview Medical Research LLC

    Canyon Country, California

  • US410 - Alliance Research Centers

    Laguna Hills, California

  • US432 - Torrance Clinical Research Institute Inc.

    Lomita, California

  • Us414 - Alexander Ford Md

    Los Angeles, California

  • US441 - Samaritan Center for Medical Research

    Los Gatos, California

  • US406 - CI Trials

    Santa Ana, California

  • US411 - Syrentis Clinical Research

    Santa Ana, California

  • US420 - Mountain View Clinical Research, INC

    Denver, Colorado

  • US447 - ASCLEPES Research Centers

    Brooksville, Florida

  • US457 - Florida Spine Institute

    Clearwater, Florida

  • US430 - South Lake Pain Institute

    Clermont, Florida

  • US434 - Finlay Medical Research

    Miami, Florida

  • US407 - Oceane 7 Medical and Research Center, Inc.

    Miami, Florida

  • US436 - Cordova Research Institute

    Miami, Florida

  • US417 - Tampa Pain Relief Center

    Tampa, Florida

  • US403 - Palm Beach Research Center

    West Palm Beach, Florida

  • US404 - Infinite Clinical Trials

    Riverdale, Georgia

  • US424 - Georgia Neurology and Sleep Medicine Assoc.

    Suwanee, Georgia

  • US431 - Injury Care Research, LLC

    Boise, Idaho

  • US437 - Great Lakes Clinical Trials LLC

    Chicago, Illinois

  • US435 - Centex Studies Inc

    Lake Charles, Louisiana

  • US448 - The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • US450 - SRI International

    Plymouth, Michigan

  • US449 - Michigan Pain Consultants

    Wyoming, Michigan

  • US433 - Creighton University - Osteoporosis Research Center

    Omaha, Nebraska

  • US419 - Manhattan Behavioral Medicine

    New York, New York

  • US440 - OnSite Clinical Solutions LLC

    Charlotte, North Carolina

  • US405 - OnSite Clinical Solutions LLC

    Hickory, North Carolina

  • US416 - Medical Research International

    Oklahoma City, Oklahoma

  • US429 - Lehigh Valley Health

    Allentown, Pennsylvania

  • US438 - Abington Neurological Associates, LTD.

    Willow Grove, Pennsylvania

  • US425 - PCPMG Clinical Research Unit LLC

    Greenville, South Carolina

  • US423 - Biopharma Informatic Inc. Research Center

    Houston, Texas

  • US443 - Centex Studies Inc

    Houston, Texas

  • US421 - Northwest Clinical Research Center

    Bellevue, Washington

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.